Induction of allergen-specific tolerance via mucosal routes

Current Topics in Microbiology and Immunology

Volumn 352, Issue 1, 2011, Pages 85-105

  Mascarell, Laurent ^a   Zimmer, Aline ^a   Van Overtvelt, Laurence ^a   Tourdot, Sophie ^a   Moingeon, Philippe ^a  

^a Research and Development   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALLERGOID GRASS EXTRACT; ARTEMISIA EXTRACT; AUTOANTIGEN; CHITOSAN; FOOD ALLERGEN; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIPID A DERIVATIVE; LIPOPEPTIDE; MITE EXTRACT; NANOPARTICLE; PEPTIDE FRAGMENT; POLLEN EXTRACT; PROBIOTIC AGENT; RECOMBINANT ALLERGEN BET V 1; RECOMBINANT ALLERGEN DER P 1; UNCLASSIFIED DRUG; VENOM; CYTOKINE; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; POLYPEPTIDE; RECOMBINANT ALLERGEN;

ALLERGY; ANAPHYLAXIS; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; ASTHMA; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; DENDRITIC CELL; DESENSITIZATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; FOOD ALLERGY; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LACTOBACILLUS PLANTARUM; LOCAL NASAL IMMUNOTHERAPY; MITE; NONHUMAN; ORAL IMMUNOTHERAPY; POLLEN; PRIORITY JOURNAL; REPEAT PROCEDURE; RESPIRATORY TRACT DISEASE; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; ALLERGIC RHINITIS; ARTEMISIA; AUTOIMMUNE DISEASE; BIRCH; CELL INFILTRATION; CELL MATURATION; DISEASE MODEL; DRUG MECHANISM; EFFECTOR CELL; GRASS POLLEN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREGULATION; RAGWEED; REGULATORY T LYMPHOCYTE;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, SUBLINGUAL; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; MUCOUS MEMBRANE;

HEXAPODA; PYROGLYPHIDAE;

EID: 80053494075     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82_2011_132     Document Type: Article

References (156)

1. Allakhverdi Z, Fitzpatrick D, Boisvert A et al (2006) Expression of CD103 identifies human regulatory T-cell subsets. J Allergy Clin Immunol 118:1342-1349 (Pubitemid 44854109)
2. Allam JP, Novak N, Fuchs C et al (2003) Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FceRI expression. J Allergy Clin Immunol 112:141-148 (Pubitemid 36819819)
3. Allam JP, Peng WM, Appel T et al (2008a) Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 121:368-374 e1
4. Allam JP, Stojanovski G, Friedrichs N et al (2008b) Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 63:720-727 (Pubitemid 351591847)
5. Andri L, Falagiani P (2003) Symptomatic relief after grass nasal immunotherapy: lasting efficacy after 4-5 years. J Investig Allergol Clin Immunol 13:228-231 (Pubitemid 38160364)
6. Andri L, Senna G (1995) Local nasal immunotherapy. Allergy 50:190
7. Andri L, Senna GE, Betteli C et al (1992) Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy 47:318-323
8. Andri L, Senna G, Betteli C et al (1993) Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract. J Allergy Clin Immunol 91:987-996 (Pubitemid 23151631)
9. Andri L, Senna G, Betteli C et al (1996) Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol 97:34-41 (Pubitemid 26045966)
10. Antunez C, Mayorga C, Corzo JL, Jurado A, Torres MJ (2008) Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration. Pediatr Allergy Immunol 19:210-218 (Pubitemid 351499165)
11. Baena-Cagnani CE, Passalacqua G, Baena-Cagnani RC, Croce VH, Canonica WG (2005) Sublingual immunotherapy in pediatric patients: beyond clinical efficacy. Curr Opin Allergy Clin Immunol 5:173-177 (Pubitemid 40434468)
12. Bagnasco M, Mariani G, Passalacqua G et al (1997) Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 100:122-129 (Pubitemid 27328540)
13. Bahceciler NN, Arikan C, Taylor A et al (2005) Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 136:287-294 (Pubitemid 40529201)
14. Bellussi L, Bologna M, Di Stanislao C et al (2002) Simplified local nasal immunotherapy in mite dust allergic rhinitis. J Investig Allergol Clin Immunol 12:42-47 (Pubitemid 34507065)
15. Benjaponpitak S,Oro A,Maguire P et al (1999) The kineticsofchangeincytokine production byCD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 103:468-475
16. Bohle B, Breitwieser A, Zwolfer B et al (2004) A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomod-ulating capacity. J Immunol 172:6642-6648 (Pubitemid 38669099)
17. Bohle B, Kinaciyan T, Gerstmayr M et al (2007) Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 120:707-713 (Pubitemid 47320765)
18. Bonifaz LC, Bonnyay DP, Charalambous A et al (2004) In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199: 815-824 (Pubitemid 38375201)
19. Bousquet J, Lockey R, Malling HJ (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102:558-562
20. Bousquet J, Scheinmann P, Guinnepain MT et al (1999) Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 54:249-260 (Pubitemid 29185286)
21. Bousquet J, Van Cauwenberge P, Khaltaev N (2001) Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147-S334
22. Buchanan AD, Green TD, Jones SM et al (2007) Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 119:199-205 (Pubitemid 46037808)
23. Burks AW, Laubach S, Jones SM (2008) Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol 121:1344-1350
24. Calamita Z, Saconato H, Pela AB, Atallah AN (2006) Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 61:1162-1172 (Pubitemid 44326350)
25. Canonica GW, Passalacqua G (2003) Noninjection routes for immunotherapy. J Allergy Clin Immunol 111:437-448 quiz 49 (Pubitemid 36337857)
26. + regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol 180:7327-7337
27. Ciprandi G, Fenoglio D, Cirillo I et al (2005) Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 95:38-44 (Pubitemid 41022771)
28. Clavel R, Bousquet J, Andre C (1998) Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 53:493-498 (Pubitemid 28248417)
29. Conti HR, Shen F, Nayyar N et al (2009) Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206:299-311
30. Cosmi L, Santarlasci V, Angeli R et al (2006) Sublingual immunotherapy with Dermatophago-ides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma-and interleukin 10-production. Clin Exp Allergy 36:261-272 (Pubitemid 43344707)
31. Cuburu N, Kweon MN, Song JH et al (2007) Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25:8598-8610 (Pubitemid 350192038)
32. D'Amato G, Lobefalo G, Liccardi G, Cazzola M (1995) A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy 25:141-148
33. Dahl R, Kapp A, Colombo G et al (2006) Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118:434-440 (Pubitemid 44160721)
34. Dahl R, Kapp A, Colombo G et al (2008) Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 121:512-518 e2
35. Daniel C, Repa A, Wild C et al (2006) Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 61:812-819 (Pubitemid 43893983)
36. Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B (2007) Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 8:1086-1094 (Pubitemid 47423756)
37. Deuschl H, Johansson GO (1977) Hyposensitization of patients with allergic rhinitis by intranasal administration of chemically modified grass pollen allergen. A pilot study. Acta Allergol 32:248-262 (Pubitemid 8134729)
38. Didier A, Melac M, Combebias A, Andre C (2006) Efficacy and safety of sublingual immunotherapy grass pollen tablets in grass pollen rhinoconjonctivitis. J Allergy Clin Immunol 117(Suppl LB5):721
39. Didier A, Melac M, Montagut A et al (2009) Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy 64:166-171
40. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F (2001) A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56:498-505 (Pubitemid 32521429)
41. Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR (2003) Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol Immunopathol (Madr) 31:270-277 (Pubitemid 37429027)
42. Durham SR, Till SJ (1998) Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 102:157-164 (Pubitemid 28406897)
43. Ebner C, Siemann U, Bohle B et al (1997) Immunological changes during specific immuno-therapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 27:1007-1015
44. Edlmayr J, Niespodziana K, Linhart B et al (2009) A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 182:6298-6306
45. El Azami El Idrissi M, Ladant D, Leclerc C (2002) The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells. Toxicon 40:1661-1665 (Pubitemid 35379718)
46. El Biaze M, Boniface S, Koscher V et al (2003) T cell activation, from atopy to asthma: more a paradox than a paradigm. Allergy 58:844-853 (Pubitemid 37046681)
47. Faria AM, Weiner HL (2005) Oral tolerance. Immunol Rev 206:232-259 (Pubitemid 41105174)
48. Faria AM, Weiner HL (2006a) Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 13:143-157 (Pubitemid 44950033)
49. Faria AM, Weiner HL (2006b) Oral tolerance and TGF-beta-producing cells. Inflamm Allergy Drug Targets 5:179-190
50. Fiocchi A, Pajno G, La Grutta S et al (2005) Safety of sublingual-swallow immunotherapy in children aged 3-7 years. Ann Allergy Asthma Immunol 95:254-258 (Pubitemid 41376795)
51. Gafvelin G, Thunberg S, Kronqvist M et al (2005) Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 138:59-66 (Pubitemid 41291566)
52. + interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy 34:1209-1219 (Pubitemid 39093059)
53. Gehlhar K, Schlaak M, Becker W, Bufe A (1999) Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 29:497-506 (Pubitemid 29179819)
54. Georgitis JW, Reisman RE, Clayton WF et al (1983) Local intranasal immunotherapy for grass-allergic rhinitis. J Allergy Clin Immunol 71:71-76 (Pubitemid 13183906)
55. Giovane AL, Bardare M, Passalacqua G et al (1994) A three year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 24:53-59 (Pubitemid 24210816)
56. Goetsch L, Gonzalez A, Plotnicky-Gilquin H et al (2001) Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae. Infect Immun 69:6434-6444 (Pubitemid 32885209)
57. Haicheur N, Benchetrit F, Amessou M et al (2003) The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol 15:1161-1171 (Pubitemid 37220490)
58. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR (1997) Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 99:254-260 (Pubitemid 27091578)
59. Hawiger D, Inaba K, Dorsett Y et al (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194:769-779 (Pubitemid 32983013)
60. Himly M, Nony E, Chabre H et al (2009) Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation. Allergy 64(7):1038-1045
61. Hisbergues M, Magi M, Rigaux P et al (2007) In vivo and in vitro immunomodulation of Der p 1 allergen-specific response by Lactobacillus plantarum bacteria. Clin Exp Allergy 37:1286-1295 (Pubitemid 47372298)
62. Horak F, Jaeger S, Worm M, Melac M, Didier A (2009) Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment. Clin Exp Allergy 39:394-400
63. Huang FP, Platt N, Wykes M et al (2000) A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 191:435-444
64. Hufnagl K, Focke M, Gruber F et al (2008) Airway inflammation induced after allergic poly-sensitization can be prevented by mucosal but not by systemic administration of poly-peptides. Clin Exp Allergy 38:1192-1202
65. Ibanez MD, Kaiser F, Knecht R et al (2007) Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 18:516-522 (Pubitemid 47206745)
66. Iwasaki A, Kelsall BL (1999) Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med 190:229-239 (Pubitemid 29354916)
67. Jeannin P, Renno T, Goetsch L et al (2000) OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol 1:502-509
68. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH (2000) Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192:1213-1222
69. Jutel M, Akdis M, Budak F et al (2003) IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33:1205-1214 (Pubitemid 36609138)
70. Jutel M, Jaeger L, Suck R et al (2005) Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116:608-613 (Pubitemid 41267135)
71. Khinchi MS, Poulsen LK, Carat F et al (2004) Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59:45-53 (Pubitemid 38167951)
72. La Rosa M, Ranno C, Andre C et al (1999) Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 104:425-432 (Pubitemid 29420442)
73. Larche M (2000) Specific immunotherapy. Br Med Bull 56:1019-1036 (Pubitemid 32417166)
74. Larche M, Wraith DC (2005) Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 11:S69-S76 (Pubitemid 40562306)
75. Larenas-Linnemann D (2009) Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr Opin Allergy Clin Immunol 9:168-176
76. Lee SE, Koh YI, Kim MK et al (2008) Inhibition of airway allergic disease by co-administration of flagellin with allergen. J Clin Immunol 28:157-165
77. Leng X, Fu YX, Ye ST, Duan SQ (1990) A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum-specific IgE antibody. Ann Allergy 64:27-31 (Pubitemid 20045372)
78. Litwin A, Flanagan M, Entis G et al (1997) Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol 100:30-38 (Pubitemid 27328528)
79. Liu YH, Tsai JJ (2005) Production of salivary immunoglobulin A and suppression of Dermatophagoides pteronyssinus-induced airway inflammation by local nasal immunother-apy. Int Arch Allergy Immunol 138:161-168
80. Liu L, Zhang M, Jenkins C, MacPherson GG (1998) Dendritic cell heterogeneity in vivo: two functionally different dendritic cell populations in rat intestinal lymph can be distinguished by CD4 expression. J Immunol 161:1146-1155 (Pubitemid 28380539)
81. Lombardi V, Van Overtvelt L, Horiot S et al (2008) Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy 38(11):1819-1829
82. Longo G, Barbi E, Berti I et al (2008) Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol 121:343-347
83. MacPherson G, Milling S, Yrlid U et al (2004) Uptake of antigens from the intestine by dendritic cells. Ann N Y Acad Sci 1029:75-82 (Pubitemid 40298518)
84. Malling HJ, Montagut A, Melac M et al (2009) Efficacy and safety of five-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunc-tivitis. Clin Exp Allergy 39:387-393
85. Marcucci F, Sensi L, Frati F et al (2001) Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy 56:1091-1095 (Pubitemid 33020652)
86. Marcucci F, Sensi L, Frati F et al (2003) Effects on inflammation parameters of a double-blind, placebo controlled 1 year course of SLIT in children monosensitized to mites. Allergy 58:657-662 (Pubitemid 36831323)
87. Marcucci F, Sensi L, Incorvaia C et al (2007) Oral reactions to sublingual immunotherapy: a bioptic study. Allergy 62:1475-1477 (Pubitemid 350045595)
88. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G (2005) Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3 year randomized controlled study. J Allergy Clin Immunol 115:1184-1188 (Pubitemid 40824587)
89. Mascarell L, Van Overtvelt L, Moingeon P (2006) Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines. Immunol Allergy Clin North Am 26:283-306 vii-viii
90. Mascarell L, Van Overtvelt L, Lombardi V et al (2007) A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route. Vaccine 26:108-118 (Pubitemid 350213205)
91. + T cells. J Allergy Clin Immunol 122:603-609 e5
92. + T cells. Clin Exp Allergy
93. Mavroleon G (1998) Restoration of cytokine imbalance by immunotherapy. Clin Exp Allergy 28:917-920 (Pubitemid 28401828)
94. Medicines CoSo (1986) Desensitising vaccines: an allergist's view. Br Med J 293:1169-1170
95. Meglio P, Bartone E, Plantamura M, Arabito E (2004) Giampietro PG: A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy 59:980-987 (Pubitemid 39141411)
96. Meglio P, Giampietro PG, Gianni S, Galli E (2008) Oral desensitization in children with immunoglobulin E-mediated cow's milk allergy-follow-up at 4 year and 8 months. Pediatr Allergy Immunol 19:412-419 (Pubitemid 351989319)
97. Meiler F, Zumkehr J, Klunker S et al (2008) In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 205:2887-2898
98. Menges M, Rossner S, Voigtlander C et al (2002) Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmu-nity. J Exp Med 195:15-21 (Pubitemid 34074492)
99. Michils A, Mairesse M, Ledent C et al (1998) Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression. J Allergy Clin Immunol 102:118-126 (Pubitemid 28345792)
100. Moller C, Dreborg S, Lanner A, Bjorksten B (1986) Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 41:271-279 (Pubitemid 16039032)
101. Moller C, Dreborg S, Ferdousi HA et al (2002) Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109:251-256 (Pubitemid 34158289)
102. Mosbech H, Dreborg S, Madsen F et al (1987) High dose grass pollen tablets used for hyposensitization in hay fever patients. A one year double blind placebo-controlled study. Allergy 42:451-455 (Pubitemid 17144412)
103. Mousavi T, Tajik N, Moradi M, Radjabzadeh MF (2008) CpG Immunotherapy in Chenopodium album sensitized mice: The comparison of IFN-gamma, IL-10 and IgE responses in intranasal and subcutaneous administrations. Clin Mol Allergy 6:10
104. Muller U, Akdis CA, Fricker M et al (1998) Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 101:747-754
105. Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194:629-644 (Pubitemid 32844773)
106. Nickelsen JA, Goldstein S, Mueller U et al (1981a) Local intranasal immunotherapy for ragweed allergic rhinitis. I. Clinical response. J Allergy Clin Immunol 68:33-40 (Pubitemid 11079115)
107. Nickelsen JA, Goldstein S, Mueller U et al (1981b) Local intranasal immunotherapy for ragweed allergic rhinitis. II. Immunologic response. J Allergy Clin Immunol 68:41-45 (Pubitemid 11079116)
108. Nickelsen JA, Georgitis JW, Mueller UR et al (1983) Local nasal immunotherapy for ragweed-allergic rhinitis. III. A two year of treatment. Clin Allergy 13:509-519 (Pubitemid 14230847)
109. Niederberger V, Horak F, Vrtala S et al (2004) Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 101(Suppl 2):14677-14682 (Pubitemid 39346742)
110. Novak N, Bieber T, Katoh N (2001) Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J Immunol 167:797-804 (Pubitemid 32660834)
111. Oida T, Zhang X, Goto M et al (2003) CD4+CD25-T cells that express latency-associated peptide on the surface suppress CD4+CD45RB high-induced colitis by a TGF-beta-dependent mechanism. J Immunol 170:2516-2522 (Pubitemid 36245641)
112. Olaguibel JM, Alvarez Puebla MJ (2005) Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol 15:9-16 (Pubitemid 40547626)
113. Pajno GB, Morabito L, Barberio G, Parmiani S (2000) Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 55:842-849 (Pubitemid 30643909)
114. Pajno GB, Peroni DG, Vita D et al (2003) Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs 5:777-781 (Pubitemid 37452626)
115. Passalacqua G, Albano M, Riccio AM, Scordamaglia A, Canonica GW (1997) Local nasal immunotherapy: experimental evidences and general considerations. Allergy 52:10-16 (Pubitemid 27232346)
116. Passalacqua G, Albano M, Fregonese L et al (1998) Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 351:629-632 (Pubitemid 28098445)
117. Passalacqua G, Guerra L, Pasquali M, Lombardi C, Canonica GW (2004) Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 93:3-12 quiz 12-3, 103
118. Passalacqua G, Altrinetti V, Mariani G et al (2005) Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects. Clin Exp Allergy 35:880-883 (Pubitemid 41032535)
119. Patriarca G, Nucera E, Roncallo C et al (2003) Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 17:459-465 (Pubitemid 36259410)
120. Pauli G, Larsen TH, Rak S et al (2008) Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 122:951-960
121. Penagos M, Compalati E, Tarantini F et al (2006) Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3-18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 97:141-148 (Pubitemid 44272577)
122. Pichler CE, Pichler WJ (2001) Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 56:301-306 (Pubitemid 32222609)
123. Pierson-Mullany LK, Jackola D, Blumenthal M (2000) Rosenberg A: Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann Allergy Asthma Immunol 84:241-243 (Pubitemid 30141606)
124. Powell RJ, Frew AJ, Corrigan CJ (2007) Durham SR: Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy 62:1335-1338 (Pubitemid 47537501)
125. Pugh CW, MacPherson GG, Steer HW (1983) Characterization of nonlymphoid cells derived from rat peripheral lymph. J Exp Med 157:1758-1779 (Pubitemid 13060881)
126. Purohit A, Niederberger V, Kronqvist M et al (2008) Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 38:1514-1525
127. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT (2008) Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 121:1467-1472, 72 e1
128. Razafindratsita A, Saint-Lu N, Mascarell L et al (2007) Improvement of sublingual immuno-therapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 120:278-285 (Pubitemid 47411528)
129. Rebien W, Puttonen E, Maasch HJ, Stix E, Wahn U (1982) Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study. Eur J Pediatr 138:341-344 (Pubitemid 12041566)
130. Robinson DS, Larche M, Durham SR (2004) Tregs and allergic disease. J Clin Invest 114:1389-1397 (Pubitemid 40385566)
131. Saint-Lu N, Tourdot S, Razafindratsita A et al (2009) Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 64:1003-1013
132. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M (2002) Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 109:455-462 (Pubitemid 34234196)
133. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT (1993) Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 178:2123-2130 (Pubitemid 23344869)
134. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT (2004) Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostim-ulatory DNA. J Allergy Clin Immunol 113:1144-1151 (Pubitemid 38857998)
135. Skripak JM, Nash SD, Rowley H et al (2008) A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 122:1154-1160
136. Song JH, Nguyen HH, Cuburu N et al (2008) Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 105:1644-1649 (Pubitemid 351346568)
137. Staden U, Rolinck-Werninghaus C, Brewe F et al (2007) Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 62:1261-1269 (Pubitemid 47537518)
138. Steinman RM, Hawiger D, Liu K et al (2003) Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 987:15-25 (Pubitemid 36584003)
139. Suffia I, Reckling SK, Salay G, Belkaid Y (2005) A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J Immunol 174:5444-5455 (Pubitemid 40593184)
140. Sun CM, Hall JA, Blank RB et al (2007) Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 204:1775-1785 (Pubitemid 47236316)
141. Sun JB, Flach CF, Czerkinsky C, Holmgren J (2008) B lymphocytes promote
142. Taudorf E, Weeke B (1983) Orally administered grass pollen. Allergy 38:561-564 (Pubitemid 14233187)
143. Taudorf E, Laursen LC, Lanner A et al (1987) Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 80:153-161 (Pubitemid 17131082)
144. Taudorf E, Laursen L, Lanner A et al (1989) Specific IgE, IgG, and IgA antibody response to oral immunotherapy in birch pollinosis. J Allergy Clin Immunol 83:589-594 (Pubitemid 19094607)
145. Taylor A, Verhagen J, Akdis CA, Akdis M (2004) T regulatory cells in allergy and health: a question of allergen specificity and balance. Int Arch Allergy Immunol 135:73-82 (Pubitemid 39279434)
146. Tighe H, Takabayashi K, Schwartz D et al (2000) Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 106:124-134 (Pubitemid 30482862)
147. Tsai JJ, Liao EC, Tsai FH, Hsieh CC, Lee MF (2009) The effect of local nasal immunotherapy in allergic rhinitis: using strips of the allergen dermatophagoides pteronyssinus. J Asthma 46:165-170
148. Urbanek R, Burgelin KH, Kahle S, Kuhn W, Wahn U (1990) Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response. Eur J Pediatr 149:545-550 (Pubitemid 20184015)
149. Van Overtvelt L, Lombardi V, Razafindratsita A et al (2008) IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol 145:152-162
150. Verhoef A, Alexander C, Kay AB, Larche M (2005) T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2:e78
151. Vourdas D, Syrigou E, Potamianou P et al (1998) Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 53:662-672 (Pubitemid 28319999)
152. Wachholz PA (2003) Durham SR: Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy 33:1171-1174 (Pubitemid 37108518)
153. Wahn U, Tabar A, Kuna P et al (2009) Efficacy and safety of five-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 123:160-166 e3
154. Wilson DR, Torres LI, Durham SR (2003) Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev CD002893
155. Wilson DR, Lima MT, Durham SR (2005) Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60:4-12
156. Winkler B, Hufnagl K, Spittler A et al (2006) The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 61:173-180 (Pubitemid 43381826)